Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial
ConclusionsFor T2DM patients treated with premixed insulin analogues, postprandial hyperglycemia played a major role in the subgroup of patients with HbA1c < 8.5%, while fasting hyperglycemia became the major contributor to overall hyperglycemia in the subgroup of patients with HbA1c ≥ 8.5%.Trial RegistrationChinese Clinical Trial Registry Identifier ChiCTR-TTRCC-12002516.FundingLilly Suzhou Pharmaceutical Co., Ltd. (Shanghai Branch, China) and National Key Program of Clinical Science of China (WBYZ2011-873).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: China Health | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Humalog | Insulin | Science